# Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

> **NCT03925896** · PHASE1 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 27 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** LMP2 Antigen-specific TCR T cells

## Key facts

- **NCT ID:** NCT03925896
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-07
- **Primary completion:** 2020-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925896, "Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03925896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*